NASDAQ · Health care

Citius Oncology, Inc. (CTOR)

It posted a net loss of $46.1M. At June 30, 2026 it held $16.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

What Citius Oncology, Inc. does

Citius Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTOR.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$23.5M	-$24.8M	-$0.34	n/a
2024	n/a	-$20.6M	-$21.1M	-$0.31	n/a
2023	n/a	-$1M	$2.4M	$0.27	n/a
2024	n/a	n/a	-$12.7M	-$0.19	n/a
2022	n/a	-$138.1K	$380.8K	$0.12	n/a

Latest SEC filings

What Citius Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 26, 2026
Annual report to shareholders ARS
August 26, 2026
Proxy statement DEF 14A
August 14, 2026
Securities offering prospectus 424B3
August 14, 2026
Quarterly report 10-Q · period to June 30, 2026
August 14, 2026
Quarterly results 8-K
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 12, 2026
Executive or director change 8-K
August 5, 2026
Securities offering prospectus 424B3
August 5, 2026
Other event 8-K
June 4, 2026
Activist stake changed SCHEDULE 13D/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 14, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CTOR

What does Citius Oncology, Inc. do?

Citius Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTOR.

Is Citius Oncology, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $46.1M.

When did Citius Oncology, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the annual report to shareholders from August 26, 2026.

Similar companies

Follow CTOR

Get an email when Citius Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CTOR: get an email when it files

Where the numbers come from

Financial figures are the values Citius Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.